Lidocain Panpharma

Lidocaine, the active ingredient in Lidocain Panpharma, is a local anesthetic (amide) presented as a sterile solution for intradermal, intravenous, and subcutaneous use. It provides reversible blockade of nerve impulse transmission for minor surgical, diagnostic and regional nerve block procedures. GNH USA supplies Lidocain Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocain Panpharma, a local anesthetic, acts on peripheral nerve sodium channels to produce reversible loss of sensation. - Minor surgical procedures: provides local anesthesia to enable pain‑free incision and manipulation. - Diagnostic procedures (e.g., skin biopsies): enables painless tissue sampling. - Regional nerve block: produces targeted anesthesia for limb or facial interventions.

Lidocain Panpharma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient burning or stinging at the injection site - Mild dizziness or light‑headedness - Nausea or metallic taste - Localized swelling or erythema

Serious or Rare Side Effects: - Systemic toxicity presenting as central nervous system symptoms, seizures, or respiratory depression - Cardiac arrhythmias, including ventricular tachycardia or heart block - Severe hypotension or cardiovascular collapse - Allergic reactions ranging from urticaria to anaphylaxis

When using Lidocain Panpharma, clinicians should observe several safety measures. - Assess patient history: identify cardiac, hepatic, renal disease or known hypersensitivity. - Avoid excessive dosing: adhere to recommended maximum dose limits for the specific route. - Use with caution in children: adjust dose based on body weight and monitor closely. - Monitor for signs of toxicity: observe central nervous system and cardiovascular status during and after administration. - Store at room temperature: keep in original container, protect from light and moisture.

Lidocain Panpharma can interact with other medications that affect cardiac conduction or drug metabolism.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase plasma lidocaine levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure. - Beta‑blockers (e.g., propranolol): may enhance lidocaine’s cardiac depressant effects.

Moderate Interactions (Monitor Closely): - Class III antiarrhythmics (e.g., amiodarone): may alter lidocaine metabolism. - Concurrent use of other local anesthetics: risk of cumulative systemic toxicity. - Diuretics (e.g., furosemide): may affect plasma protein binding and increase free drug concentration.